Use of Ranibizumab With Mitomycin C During Trabeculectomy (OCTOPUS)

This study is ongoing, but not recruiting participants.
Genentech, Inc.
Information provided by (Responsible Party):
University of Colorado, Denver Identifier:
First received: April 15, 2008
Last updated: June 10, 2014
Last verified: June 2014

April 15, 2008
June 10, 2014
April 2008
September 2014   (final data collection date for primary outcome measure)
to assess ocular adverse events of combination ranibizumab and MMC therapy at 6 months [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00661583 on Archive Site
  • to determine percent of subjects with a qualified success and viable bleb at 6 months (IOP between 6mm Hg and 22 mm Hg with pressure controlled with and without adjunctive medications) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • to determine mean change in in intraocular pressure and in visual acuity at 3 months and at 6 months [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
Use of Ranibizumab With Mitomycin C During Trabeculectomy
Occlusion Prevention for TrabeculectOmy Procedures Using Combination Ranibizumab and Mitomycin C (MMC) During Surgery (OCTOPUS Study)

A common problem after undergoing trabeculectomy, surgery to create a bleb (blister or bubble) to reduce intraocular pressure, is scarring of the opening. This scarring prevents fluid drainage and interferes with the proper function of the bleb. This study will add ranibizumab to the standard of care treatment as ranibizumab may compliment mitomycin C in the prevention of scarring at the bleb site potentially adding to the effectiveness of mitomycin C.

The study will access ocular adverse events of adding ranibizumab to standard of care treatment at 6 months after trabeculectomy.

Not Provided
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Trabeculectomy
  • Glaucoma
Drug: ranibizumab
0.5mg of ranibizumab intravitreally injected after surgery and at 1 month if needed
Active Comparator: 1
standard of care
Intervention: Drug: ranibizumab
Kahook MY. Bleb morphology and vascularity after trabeculectomy with intravitreal ranibizumab: a pilot study. Am J Ophthalmol. 2010 Sep;150(3):399-403.e1. doi: 10.1016/j.ajo.2010.03.025. Epub 2010 Jun 8.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Active, not recruiting
September 2014
September 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • glaucoma
  • undergoing trabeculectomy
  • 21 years of age or older

Exclusion Criteria:

  • pregnancy or lactation
  • any condition the investigator believes would impose a significant hazard to the patient if investigational therapy were initiated
  • history of ocular surface disease
  • cataract surgery in the past 6 months
  • history of active inflammatory, infectious or idiopathic keratitis
21 Years and older
Contact information is only displayed when the study is recruiting subjects
United States
University of Colorado, Denver
University of Colorado, Denver
Genentech, Inc.
Study Director: Malik Y. Kahook, MD Rocky Mountain Lions Eye institute
University of Colorado, Denver
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP